Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
PhaseBio Pharmaceuticals Inc
| Metric | PhaseBio Pharmaceuticals Inc Healthcare |
|---|---|
| Quality Score | 49 / 100 |
| Revenue (latest) | $11M |
| Net income (latest) | −$131M |
| Operating margin | −991.2% |
| Net margin | −1210.1% |
| Return on equity | 140.9% |
| Return on assets | −216.5% |
| Return on capital (ROCE) | −328.8% |
| Debt / equity | — |
| Revenue growth (YoY) | 3284.7% |
| Altman Z″ (distress) | -31.39 |
| Accruals / assets | −138.2% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.